Bijal D. Shah, MD

Articles

Dr. Shah on Results Seen With Brexucabtagene Autoleucel in Relapsed/Refractory B-ALL

June 11th 2021

Bijal Shah, MD, MS, discusses the results seen with brexucabtagne autoleucel in patients with relapsed/refractory B-cell acute lymphoblastic leukemia, as demonstrated in the phase 2 ZUMA-3 trial.

Dr. Shah on the Use of Tisagenlecleucel in Pediatric ALL

September 21st 2019

Bijal D. Shah, MD, associate professor, Department of Malignant Hematology, Moffitt Cancer Center, discusses the use of CAR T-cell therapy in patients with pediatric acute lymphoblastic leukemia (ALL).

Dr. Shah on Ongoing Trials in MCL

April 23rd 2019

Bijal D. Shah, MD, oncologist/hematologist, Moffitt Cancer Center, discusses ongoing trials in the field of mantle cell lymphoma (MCL).

Dr. Shah on Challenges With Developing MCL Clinical Trials

April 19th 2019

Bijal D. Shah, MD, associate member, Moffitt Cancer Center, assistant professor of oncology, University of South Florida, discusses challenges with developing mantle cell lymphoma clinical trials.

Dr. Shah on Overcoming Resistance to BTK Inhibitors in MCL

April 17th 2019

Bijal D. Shah, MD, associate member, Department of Malignant Hematology, Moffitt Cancer Center, discusses overcoming resistance to BTK inhibitors in the treatment of mantle cell lymphoma.

Dr. Shah on Challenges in Treating Patients With High-Risk MCL

November 6th 2018

Bijal D. Shah, MD, associate member, Department of Malignant Hematology, Moffitt Cancer Center, discusses the challenges in treating patients with high-risk mantle cell lymphoma (MCL).

Dr. Shah on Challenges of CAR T-Cell Clinical Trials in MCL

October 17th 2018

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, assistant professor of oncology, University of South Florida, discusses the challenges of developing clinical trials for CAR T cells in mantle cell lymphoma.

Dr. Shah on Treatment of Patients with p53-Mutated MCL

September 20th 2018

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, assistant professor of oncology, University of South Florida, discusses the treatment of patients with p53-mutated mantle cell lymphoma.

Dr. Shah Compares Toxicity Profiles of Ibrutinib and Acalabrutinib

September 11th 2018

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, assistant professor of oncology, University of South Florida, compares toxicity profiles of ibrutinib and acalabrutinib.

Dr. Shah Compares BTK Inhibitors for Mantle Cell Lymphoma

September 6th 2018

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, assistant professor of oncology, University of South Florida, compares the 2 available BTK inhibitors for patients with mantle cell lymphoma.

Dr. Shah on the Importance of CAR T-Cell Therapy for ALL

November 23rd 2017

Bijal D. Shah, MD, medical oncology, Moffit Cancer Center, discusses the importance of chimeric antigen receptor (CAR) T-cell therapy for patients with acute lymphoblastic leukemia (ALL).

Dr. Shah Discusses Sequencing for MCL

November 18th 2017

Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses the sequencing of agents for patients with mantle cell lymphoma (MCL).

Dr. Shah on Toxicites Associated With CAR T-Cell Therapy

November 10th 2017

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, comments on the toxicities associated with using chimeric antigen receptor (CAR) T-cell therapy in patients with leukemia.

Dr. Shah Discusses P53-Mutated Mantle Cell Lymphoma

October 24th 2017

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, discusses treatment for patients with p53-mutated mantle cell lymphoma (MCL).

Dr. Shah Discusses Autologous Transplant in MCL

October 18th 2017

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, discusses autologous stem cell transplant (ASCT) in mantle cell lymphoma (MCL).

Dr. Shah on Excitement With Venetoclax in Patients With MCL

August 22nd 2017

Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses the potential with venetoclax (Venclexta) in patients with mantle cell lymphoma (MCL).

Dr. Shah on Options for Ibrutinib-Intolerant Patients With MCL

August 11th 2017

Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses a therapeutic option on the horizon for patients with mantle cell lymphoma (MCL) who are intolerant to ibrutinib (Imbruvica).

Dr. Shah on Emerging Developments in MCL

July 24th 2017

Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses some of the emerging developments on the horizon in mantle cell lymphoma (MCL).

Dr. Shah on CAR T-cell Therapy's Effectiveness in ALL

July 11th 2017

Bijal D. Shah, MD, medical oncology, of Moffit Cancer Center, explains why chimeric antigen receptor (CAR) T-cell therapy has shown the most progress in acute lymphoblastic leukemia (ALL).

Dr. Shah on Status of CAR T-cell Therapies in ALL

May 26th 2017

Bijal D. Shah, MD, medical oncology, of Moffit Cancer Center, discusses the status of chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia (ALL).